Eisai’s Fycompa (perampanel) has received approval from the European Commission as an adjunct treatment for partial-onset seizures in children 4 years and older, and for seizures in children 7 years and older with generalized epilepsy.

The approval was supported by positive results from two late-stage global trials that assessed patients for up to 41 weeks following treatment.

Pediatric epilepsy can pose a range of developmental problems for children, including neurocognitive, behavioral, social and psychiatric issues. In Europe, epilepsy affects an estimated 1 million children, with 100,000 new cases diagnosed annually.